Dr Schiller is a founding partner of Digestive Health Associates of Texas, located in Dallas, the largest private single-specialty gastroenterology practice in the United States. He is also program director for Gastroenterology Fellowship and chair of the Institutional Review Boards for Human Subject Protection at Baylor University Medical Center at Dallas.

Dr Schiller earned a medical degree at Jefferson Medical College of Thomas Jefferson Univesity in Philadelphia, Pennsylvania. He completed an internship and residency in internal medicine at Temple University Hospital in Philadelphia. Dr Schiller received training in gastroenterology at The University of Texas Southwestern Medical School at Dallas, where he was awarded 2 teaching fellowships. He then continued research activities with Dr John Fordtran at Baylor University Medical Center.

Dr Schiller has been named to “Best Doctors” lists locally and nationally. He is an elected fellow of the American College of Physicians and American College of Gastroenterology (ACG) and serves as secretary of the ACG. He has authored or coauthored many book chapters and contributed articles to journals such as Gastroenterology, Digestive Diseases and Sciences, and The Journal of Clinical Investigation.

Digestive Health Associates of Texas, P.A., (DHAT) is the largest gastroenterology physician group in the country. With more than 30 locations covering a 100-mile radius, DHAT provides health care services for the entire Dallas/Fort Worth Metroplex. The provision of high quality, cost-effective patient care is the primary goal of DHAT physicians. By maintaining a staff of exceptional sub-specialists, DHAT is uniquely qualified to deliver services supporting the full spectrum of an individual's digestive health care. Our physicians share expertise, talent and technology to promote the patient's positive outcome, comfort and quality of life. In addition, excellent nursing staff and other health care professionals support our physicians.

 A Phase III, multicenter, placebo-controlled, randomized, double-blind durability and retreatment study to evaluate the safety and efficacy of PROCHYMAL(R) (ex vivo cultured adult human mesencymal stem cells) intravenous infusion for the maintenance and re-induction of clinical benefit and remission in subjects experiencing treatment-refractory moderate-to-severe Crohn's disease

 Humanitarian Use Device Protocol for Enterra(R) Therapy: Gastric Electrical Stimulation to Treat Nausea and Vomiting Associate with Gastroparesis